Last reviewed · How we verify
cART
cART is a chimeric antigen receptor T-cell therapy that engineers a patient's own T cells to recognize and kill cancer cells expressing a specific tumor antigen.
cART is a chimeric antigen receptor T-cell therapy that engineers a patient's own T cells to recognize and kill cancer cells expressing a specific tumor antigen. Used for Hematologic malignancies (specific indications depend on CAR construct and clinical development stage).
At a glance
| Generic name | cART |
|---|---|
| Also known as | Combination antiretroviral therapy, Antiretroviral therapy |
| Sponsor | LI Taisheng |
| Drug class | CAR-T cell therapy |
| Target | Tumor-associated antigen (specific target depends on formulation) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
cART (chimeric antigen receptor T-cell therapy) involves extracting T cells from a patient, genetically modifying them to express a chimeric antigen receptor that targets tumor-associated antigens, expanding these engineered cells ex vivo, and reinfusing them to attack malignant cells. This approach combines the specificity of antibody targeting with the cytotoxic power of T-cell immunity.
Approved indications
- Hematologic malignancies (specific indications depend on CAR construct and clinical development stage)
Common side effects
- Cytokine release syndrome
- Neurotoxicity
- Cytopenias
- Infections
Key clinical trials
- Descartes-08 for Patients With Systemic Lupus Erythematosus (PHASE2)
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- Co-administration of CART22-65s and huCART19 for B-ALL (PHASE1, PHASE2)
- A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu... (NA)
- CART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension (NA)
- A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL (NA)
- Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction (PHASE2)
- Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cART CI brief — competitive landscape report
- cART updates RSS · CI watch RSS
- LI Taisheng portfolio CI